Handelsavisen
prelaunch
Companies Healthcare HEALTH.HE
HE
HEALTH.HE Nasdaq Helsinki Biotechnology & Medical Research

Nightingale Health Oyj

€0,99
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
40,0M EUR
P/E
EV / Rev
Div yield
0,00 %
Op margin
-413,7 %
ROE
-27,9 %
Net margin
-393,4 %
Debt / equity
0,05
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

HEALTH.HE operates in the healthcare diagnostics industry, providing services and solutions related to medical diagnostics and research.

Business. HEALTH.HE is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Finland and is primarily listed on the Nasdaq Helsinki exchange under the ticker HEALTH.HE. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target1,70

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
1,70
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
-27,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning HEALTH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to HEALTH.HE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    HEALTH.HE is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Finland and is primarily listed on the Nasdaq Helsinki exchange under the ticker HEALTH.HE. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    HEALTH.HE has a market price of 0.86 EUR and a market cap of 34,860,253.94 EUR, indicating a relatively small capitalization. The company's price-to-book ratio is 0.53, and its price-to-tangible-book ratio is also 0.53, suggesting that the company's market value is significantly lower than its book value. The enterprise value to EBITDA ratio is 0.147, and the enterprise value to revenue ratio is -0.61, indicating a negative valuation multiple.

    In terms of profitability, HEALTH.HE has a return on equity of -0.279 and a return on assets of -0.2478, both of which are negative, indicating that the company is not generating returns for its shareholders or assets. The company's operating income and net income are both negative, at -19,417,000 EUR and -18,462,000 EUR, respectively, showing that the company is currently operating at a loss.

    HEALTH.HE's revenue is 4,693,000 EUR, and its gross profit is 3,555,000 EUR. The company's revenue concentration is not specified, but the lack of segment data suggests that the company may not have a diversified revenue stream. The company's capital expenditure is -4,154,000 EUR, indicating that it is investing in its operations.

    Looking at the company's growth trajectory, HEALTH.HE's operating cash flow is -10,108,000 EUR, and its free cash flow is -14,322,000 EUR, both of which are negative, indicating that the company is not generating positive cash flow from its operations. The company's liquidity is low, with a current ratio of 8.8, suggesting that it has sufficient current assets to cover its current liabilities.

    In terms of risk factors, HEALTH.HE has a low liquidity risk and a low dilution risk. The company has no immediate filing-based liquidity or dilution flags, indicating that it is not currently facing significant financial risks. The company's debt-to-equity ratio is 0.05, indicating that it has a low level of debt relative to its equity.

    Recent events related to HEALTH.HE include analyst estimates, with a mean price target of 1.70 EUR and a mean recommendation of 2.00, indicating a neutral stance from analysts. The company has one buy recommendation and no strong-buy or hold recommendations, suggesting that analysts are not overly optimistic about the company's future performance.

    Key takeaways
    • HEALTH.HE is a small-cap healthcare diagnostics company with a market cap of 34,860,253.94 EUR.
    • The company is currently operating at a loss, with negative operating and net income.
    • HEALTH.HE has a low liquidity risk and a low dilution risk, with no immediate filing-based flags.
    • Analysts have a neutral stance on the company, with a mean price target of 1.70 EUR.
    • The company's financial metrics, including return on equity and return on assets, are negative, indicating poor performance.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    €0,99
    Market cap
    €34.9M
    Enterprise value
    -€2.9M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    0.5x
    P / Tangible book
    0.5x
    Tangible book
    €66.2M
    Net cash
    €37.7M
    Current ratio
    8.8
    Debt / equity
    0.1
    ROA
    -24.8%
    ROE
    -27.9%
    Cash conversion
    55.0%
    CapEx / revenue
    -88.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,27
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,27
    Revenueno estimateno estimate7,6M EUR
    Operating incomeno estimateno estimate-16,4M EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target€1,70 · Median €1,70
    Low €1,70High €1,70
    Operating income · consensus-16,4M EUR
    EPS surprise
    −14,8 %
    reported vs consensus · miss
    Revenue surprise
    −38,2 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€1,70
    Mean€1,70
    Median€1,70
    High€1,70
    Spot€0,99
    +72.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-413,7 %Below median
    Net Margin-393,4 %Below median
    ROE-27,9 %Below median
    Capex / Rev-88,5 %Bottom quartile
    D/E0,05Below median
    Cash Conv0,55Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • HEALTH.HE Market data — financials · 2026-05-28
    • Nightingale Health Oyj Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    HEALTH.HECanonical
    Nasdaq Helsinki · EUR

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage